Navigation Links
Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation
Date:11/11/2008

New post-hoc analysis from ATHENA Study showed that Multaq(R) on top of standard therapy significantly decreased the total number of hospital days by 28% in patients with atrial fibrillation or flutter

NEW ORLEANS, Nov. 11 /PRNewswire-FirstCall/ -- New data from the landmark ATHENA trial showed that dronedarone significantly reduced the incidence and total duration of hospital stays among patients with atrial fibrillation/atrial flutter (AF/AFL). This post-hoc analysis was presented at the 2008 American Heart Association Scientific Sessions in New Orleans, Louisiana.

In this new analysis, dronedarone significantly reduced the total number of hospital days by 28 percent (p<0.001) versus placebo (9,995 days vs. 13,986 days), and decreased by 35 percent (p<0.001) the total length of time spent in hospital for cardiovascular reasons (5,875 days vs. 9,073 days).

In addition to the demonstrated reduction of AF-related hospitalization by 37 percent (p<0.001), dronedarone reduced the incidence of first non-AF related CV hospitalization (e.g. myocardial infarction or unstable angina by 14 percent (p=0.016). Dronedarone did not increase the incidence of non-cardiovascular hospitalizations in comparison to the placebo arm.

"The incidence of AF-related hospital admissions has dramatically increased in recent years, and therapeutic solutions to reduce this burden are needed," said Dr. Christian Torp-Pedersen from the Gentofte University Hospital, Copenhagen, Denmark and a member of the steering committee of the ATHENA study. "These new ATHENA data showed that, for the first time, an anti-arrhythmic drug significantly and consistently reduced hospitalization incidence and duration, which led to a substantial reduction of total hospitalization burden in this patient population."

A second post-hoc analysis from ATHENA also presented during the AHA, confirmed the rhythm and rate controlling properties of dronedarone, previously demonstrated
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
2. ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
3. ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
4. Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
5. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
6. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
7. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
8. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
9. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
10. Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture
11. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... TAUNTON, Mass. , May 20, 2013 /PRNewswire/ ... Inc. ("OSI")  whose subsidiary companies include OMNIlife science®, ... experienced directors to their Board.  Guy ... serve as the Chairman of the Board of ... will join as a director. Before ...
(Date:5/20/2013)... LAVAL, Quebec , May 20, 2013  Valeant Pharmaceuticals ... announced members of its senior management team will make a ... Conference on Tuesday, June 11, 2013 at 9:20 a.m. PT. ... Los Angeles, CA. A ... available on the company,s Web site at www.valeant.com . ...
(Date:5/20/2013)... 20, 2013  Upsher-Smith Laboratories, Inc., a specialty ... treatments for diseases of the central nervous system, ... website, upsher-smith.com . The new site celebrates ... of the company,s mission statement – Advancing Pharmacotherapy, ... around people with a story to tell, a ...
Breaking Medicine Technology:Orthopaedic Synergy, Inc. Announces Key Additions to the Board of Directors 2Orthopaedic Synergy, Inc. Announces Key Additions to the Board of Directors 3Upsher-Smith Introduces Newly Redesigned Corporate Website 2
(Date:5/21/2013)... May 21, 2013 Joe Vitale, a positive ... early adapter of the Fisker electric car. After a year ... since the car company went bankrupt, the bestselling author turned ... , "It's a gas guzzler's anthem," says Vitale, 59, ... album, "Sun Will Rise." , Owning this Fisker was ...
(Date:5/21/2013)... 21, 2013 Limited mobility affects ... Not only is it more difficult to walk around, but ... Fortunately, there are a variety of medical products made to ... product is the raised toilet seat. , Raised toilet ... easier to stand back up or sit down. They come ...
(Date:5/20/2013)... 2013 This week has been dedicated as ... (May 19th-May 25th) is an awareness campaign designated to help ... encouraging dog owners to properly train their pets, and educate ... dog bite lawyers at Buckfire & Buckfire, P.C. represent ... Michigan. The personal injury law firm is a large advocate ...
(Date:5/20/2013)... 2013 Recent environmental concerns have ... green and sustainable inputs in packaging products. As ... to promote the use of sustainable materials, thereby ... Services industry . “Tax subsidies and operating cost ... industry analyst Deonta Smith. “For example, many packaging ...
(Date:5/20/2013)... Daily Gossip, online magazine about lifestyle, health and sports issues, ... can help them overcome one of the most spread skin ... Vitiligo Treatment System has created a buzz on the ... from the persons who have tried it. Its principles have ... some of the people who tried it and managed to ...
Breaking Medicine News(10 mins):Health News:Upset Fisker Owner Records Gas Guzzler Anthem 2Health News:JustHomeMedical.com Launches Raised Toilet Seats Category 2Health News:Buckfire & Buckfire, P.C. Dog Bite Lawyers in Michigan Discuss National Dog Bite Prevention Week 2Health News:Packaging and Labelling Services in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Packaging and Labelling Services in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:New Natural Vitiligo Treatment System That Helps People Treat Vitiligo Permanently Revealed by Daily Gossip Magazine 2
... Invasive plant species have long had a reputation as ... Stan Harpole, assistant professor of ecology, evolution and organismal ... team of more than 70 researchers working at 65 sites ... if it is true that problematic invasive species often spread ...
... CA (February 28, 2011) Eating more tomatoes and tomato ... of conditions such as cancer, osteoporosis and cardiovascular disease, ... of Lifestyle Medicine , (published by SAGE). Of ... tomato products than any others. Researchers Britt Burton-Freeman, PhD, ...
... -- For women with uterine fibroids, three treatments have ... improvements in quality of life, according to a new ... their childbearing years develop uterine fibroids, which are benign ... patients experience heavy bleeding, pain and infertility, according to ...
... SMOKING CESSATION HIGHER WITH VARENICLINE COMPARED WITH PLACEBO IN ... patients with chronic obstructive pulmonary disease (COPD) have higher ... a multinational study involving 27 centers, researchers from UCLA ... were randomized to receive either varenicline (N=250) or placebo ...
... for localized non-small cell lung cancers, may be unnecessary in ... published in the March issue of the Journal of ... Association for the Study of Lung Cancer. The risk ... a maximum standard uptake value (maxSUV) of 2.0 or a ...
... affect drug recommendations, with free journals positively recommending ... usually recommending against the use of the drugs, ... ( Canadian Medical Association Journal ) (pre-embargo link ... about corporate influence on educational medical journals, although ...
Cached Medicine News:Health News:Global ISU study: Invasive species widespread, but not more than at home range 2Health News:Health benefits of eating tomatoes emerge 2Health News:Uterine Fibroid Treatments Seem to Boost Quality of Life 2Health News:Journal 'Chest': News briefs from the March 2011 issue 2Health News:Lymph node dissection is not essential in small screen-detected lung cancers, new research shows 2Health News:The influence of advertising on drug recommendations 2
... Extremely accurate detections of ... well as glaucoma in ... be performed. Smooth operation ... perimetry. High accuracy of ...
... FDT is a breakthrough in visual field testing ... in pre-test. Introducing FDT, the first visual field ... enough to be used even in pre-test. Affordably ... trials behind it to validate performance. The instrument ...
... Matrix represents the latest breakthrough in ... technology, the Humphrey Matrix will help ... evaluation and assess treatment alternatives. Enhanced ... provide complete long-term glaucoma care for ...
... Exceptional comfort for those with ... Toric soft contact lenses let you enjoy ... other soft toric lensa difference youll especially ... throughout the day., This exceptional level of ...
Medicine Products: